These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 12615714)
1. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Hempen PM; Zhang L; Bansal RK; Iacobuzio-Donahue CA; Murphy KM; Maitra A; Vogelstein B; Whitehead RH; Markowitz SD; Willson JK; Yeo CJ; Hruban RH; Kern SE Cancer Res; 2003 Mar; 63(5):994-9. PubMed ID: 12615714 [TBL] [Abstract][Full Text] [Related]
2. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171 [TBL] [Abstract][Full Text] [Related]
3. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Jung B; Doctolero RT; Tajima A; Nguyen AK; Keku T; Sandler RS; Carethers JM Gastroenterology; 2004 Mar; 126(3):654-9. PubMed ID: 14988818 [TBL] [Abstract][Full Text] [Related]
4. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells. Rossi MR; Ionov Y; Bakin AV; Cowell JK Cancer Genet Cytogenet; 2005 Dec; 163(2):123-9. PubMed ID: 16337854 [TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059 [TBL] [Abstract][Full Text] [Related]
6. Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): a gene-dependent effect on the cell surface glycan profile. Patsos G; André S; Roeckel N; Gromes R; Gebert J; Kopitz J; Gabius HJ Glycobiology; 2009 Jul; 19(7):726-34. PubMed ID: 19293232 [TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation. Kim WS; Park C; Hong SK; Park BK; Kim HS; Park K Anticancer Res; 2000; 20(3A):1499-502. PubMed ID: 10928062 [TBL] [Abstract][Full Text] [Related]
8. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359 [TBL] [Abstract][Full Text] [Related]
9. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line. Park B; Jang JS; Park K Int J Oncol; 2000 Sep; 17(3):473-8. PubMed ID: 10938386 [TBL] [Abstract][Full Text] [Related]
10. Significance of mutations in TGFBR2 and BAX in neoplastic progression and patient outcome in sporadic colorectal tumors with high-frequency microsatellite instability. Fernández-Peralta AM; Nejda N; Oliart S; Medina V; Azcoita MM; González-Aguilera JJ Cancer Genet Cytogenet; 2005 Feb; 157(1):18-24. PubMed ID: 15676142 [TBL] [Abstract][Full Text] [Related]
11. Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. Chung H; Young DJ; Lopez CG; Le TA; Lee JK; Ream-Robinson D; Huang SC; Carethers JM PLoS One; 2008; 3(10):e3463. PubMed ID: 18941508 [TBL] [Abstract][Full Text] [Related]
12. Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells. Miyafuji Y; Zhong X; Uchida I; Koi M; Hemmi H J Cell Physiol; 2001 Jun; 187(3):356-64. PubMed ID: 11319759 [TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044 [TBL] [Abstract][Full Text] [Related]
14. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin. Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738 [TBL] [Abstract][Full Text] [Related]
15. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Myeroff LL; Parsons R; Kim SJ; Hedrick L; Cho KR; Orth K; Mathis M; Kinzler KW; Lutterbaugh J; Park K Cancer Res; 1995 Dec; 55(23):5545-7. PubMed ID: 7585631 [TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Parsons R; Myeroff LL; Liu B; Willson JK; Markowitz SD; Kinzler KW; Vogelstein B Cancer Res; 1995 Dec; 55(23):5548-50. PubMed ID: 7585632 [TBL] [Abstract][Full Text] [Related]
17. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Jung B; Smith EJ; Doctolero RT; Gervaz P; Alonso JC; Miyai K; Keku T; Sandler RS; Carethers JM Int J Cancer; 2006 May; 118(10):2509-13. PubMed ID: 16380996 [TBL] [Abstract][Full Text] [Related]
18. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer. Sakaguchi J; Kyo S; Kanaya T; Maida Y; Hashimoto M; Nakamura M; Yamada K; Inoue M Gynecol Oncol; 2005 Sep; 98(3):427-33. PubMed ID: 15993480 [TBL] [Abstract][Full Text] [Related]
19. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Grady WM; Myeroff LL; Swinler SE; Rajput A; Thiagalingam S; Lutterbaugh JD; Neumann A; Brattain MG; Chang J; Kim SJ; Kinzler KW; Vogelstein B; Willson JK; Markowitz S Cancer Res; 1999 Jan; 59(2):320-4. PubMed ID: 9927040 [TBL] [Abstract][Full Text] [Related]
20. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer. Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]